In quick turn­around, FDA lifts full clin­i­cal hold on Pro­tag­o­nist's blood can­cer pro­gram

Not even a month af­ter be­ing slapped with a full clin­i­cal hold on all stud­ies re­lat­ed to a blood can­cer pro­gram, Pro­tag­o­nist Ther­a­peu­tics saw reg­u­la­tors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER